Merck
CN

Sodium bicarbonate supplements for treating acute kidney injury.

The Cochrane database of systematic reviews (2012-06-15)
Jonathan Hewitt, Mark Uniacke, Navjyot K Hansi, Gopalakrishnan Venkat-Raman, Kathryn McCarthy
摘要

Acute kidney injury (AKI) is a common, serious, but potentially treatable condition. Because AKI is often associated with acidosis, it has become common practice to recommend administration of sodium bicarbonate to correct acid imbalance. To assess the benefits and harms of the use of sodium bicarbonate for people with AKI. The primary outcome measure was all-cause mortality, and secondary outcome measures were patients' need for renal replacement therapy; return to baseline kidney function; and overall survival. In November 2011 we searched the Cochrane Renal Group's Specialised Register using keywords relevant to this review. The register is populated using searches of Ovid MEDLINE, the Cochrane Central Register of Controlled Trials, EMBASE and handsearching records from renal-related journals and conference proceedings. All randomised controlled trials (RCTs) that investigated the use of sodium bicarbonate supplements, administered by any route, for the treatment of adults with AKI were to be included. The search strategy did not restrict inclusion based on an upper age limit or publication language. We did not consider inclusion of studies that investigated use of sodium bicarbonate for AKI prevention. All authors planned to independently assess and extracted information. Information was to be collected on methods, participants, interventions and outcomes. Results were to be expressed as risk ratios (RR) for dichotomous outcomes or as mean differences (MD) for continuous data with 95% confidence intervals (CI). Although our literature search identified four studies, none of these met our predetermined selection criteria. Hence, no suitable studies were identified for inclusion in this review. We found no RCT evidence - supportive or otherwise - for the use of sodium bicarbonate for people with AKI. We concluded that there is an urgent need for well conducted RCTs in this area.

材料
货号
品牌
产品描述

Sigma-Aldrich
碳酸氢钠, powder, BioReagent, for molecular biology, suitable for cell culture, suitable for insect cell culture
Sigma-Aldrich
碳酸氢钠, ACS reagent, ≥99.7%
Sigma-Aldrich
碳酸氢钠 溶液, solution (7.5%), sterile-filtered, BioReagent, suitable for cell culture
Sigma-Aldrich
碳酸氢钠, ReagentPlus®, ≥99.5%, powder
Sigma-Aldrich
碳酸氢钠, BioXtra, 99.5-100.5%
Sigma-Aldrich
碳酸氢钠, puriss., meets analytical specification of Ph. Eur., BP, USP, FCC, E500, 99.0-100.5%, powder
Supelco
碳酸氢钠溶液, 0.1 M NaHCO3 in water, eluent concentrate for IC
USP
碳酸氢钠, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
碳酸氢钠, tested according to Ph. Eur.
Sigma-Aldrich
碳酸氢钠, anhydrous, free-flowing, Redi-Dri, ReagentPlus®, ≥99.5%
Sigma-Aldrich
碳酸氢钠, −40-+140 mesh, ≥95%
Sigma-Aldrich
重碳酸钠-12C, 99.9 atom % 12C
Sigma-Aldrich
碳酸氢钠, Vetec, reagent grade, 99%